Close
Help
Need Help?



Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study

Submit a Paper


Libertas Analytics


1830 Article Views

Publication Date: 25 Sep 2008

Journal: Clinical Medicine Insights: Oncology

Citation: Clinical Medicine: Oncology 2008:2 533-538

CMIonc
journal

193,124 Article Views

3,608,193 Libertas Article Views

More Statistics

Z. Einbeigi1, D. Bergström2, T. Hatschek3 and M. Malmberg4

1Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. 2Roche AB, Stockholm, Sweden. 3Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden. 4Department of Oncology, Helsingborg Hospital, Helsingborg, Sweden.

Abstract

Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m2, paclitaxel 155 mg/m2 (both day 1) and capecitabine 665 mg/m2 twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.


Post a Comment

x close

Discussion Add A Comment
No comments yet...Be the first to comment.


share on

Our Service Promise

  • Prompt Processing (Average 3 Weeks)
  • Fair & Constructive Peer Review
  • Professional Author Service
  • High Visibility
  • High Readership
  • What Our Authors Say

Quick Links

Follow Us We make it easy to find new research papers. RSS Feeds Email Alerts Twitter

BROWSE CATEGORIES